Investors should monitor upcoming FDA guidance on the GBM regulatory pathway in the second half of 2026 and final mOS data presentations in mid-to-late 2026, which could serve as major value inflection points. The extended cash runway reduces near-term dilution risk.
Price Chart
Executive Summary
IN8bio reported strong clinical data in glioblastoma showing a 97% improvement in median progression-free survival with its DeltEx DRI therapy versus standard of care, alongside a 36% year-over-year reduction in net loss and a strengthened cash position of $27.1 million. The company also closed a $20.1 million initial tranche of a private placement, extending its cash runway into the first half of 2027 and supporting advancement of its gamma-delta T cell engager platform.
Key Financial Metrics
Key Facts
- Updated GBM data showed mPFS of 13.0 months vs. 6.6 months for SOC control (+97%), with median OS not yet reached at 17.2+ months
- No dose-limiting toxicities, CRS, ICANS, or TIAN observed, indicating a favorable safety profile
- Cash position increased to $27.1 million as of Dec 31, 2025, from $11.1 million in the prior year
- Net loss reduced by 36% YoY to $19.4 million in 2025 from $30.4 million in 2024
- Closed $20.1 million initial tranche of $40.2 million private placement; net proceeds of $18.5 million extend cash runway to mid-2027
- Proceeds to support IND-enabling studies for INB-619 γδ TCE and FDA discussions on GBM clinical pathway
- Promoted Kate Rochlin, Ph.D., to President and COO in February 2026
Financial Impact
Reduced annual net loss by $11.0 million YoY; cash position more than doubled to $27.1 million; $18.5 million net proceeds from financing
Risk Factors
- Clinical development risks including potential delays or negative outcomes in ongoing or future trials
- Regulatory uncertainty regarding approval pathways for novel γδ T cell therapies
- Dependence on successful execution of IND-enabling studies and future financing rounds beyond 2027
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255081 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 20w ago | Press Release | $1.54 $1.04 | ▼ −32.47% | ▼ −34.97% | $0.9804 (−36.34%) |
Jun 1, 2026 21w ago | 8-K | $1.73 $1.17 | ▲ +32.37% | ▲ +33.60% | $0.9804 (+43.33%) |
Jun 1, 2026 21w ago | 424B5 | $1.73 $1.17 | ▲ +32.37% | ▲ +33.60% | $0.9804 (+43.33%) |
May 18, 2026 23w ago | S-3/A | $1.45 $1.18 | ▲ +18.62% | ▲ +24.91% | $0.9804 (+32.39%) |
May 7, 2026 24w ago | 8-K | $1.58 $0.9601 | ▼ −39.23% | ▼ −44.07% | $0.9804 (−37.95%) |
Mar 26, 2026 30w ago | DEFA14A | $1.41 $1.51 | ▲ +7.09% | ▼ −8.97% | $0.9804 (−30.47%) |
Mar 12, 2026 32w ago | Press Release | $1.89 $1.44 | ▼ −23.81% | ▼ −35.42% | $0.9804 (−48.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers